212 related articles for article (PubMed ID: 28011157)
1. Increased Identification of Candidates for High-Risk Breast Cancer Screening Through Expanded Genetic Testing.
Rosenthal ET; Evans B; Kidd J; Brown K; Gorringe H; van Orman M; Manley S
J Am Coll Radiol; 2017 Apr; 14(4):561-568. PubMed ID: 28011157
[TBL] [Abstract][Full Text] [Related]
2. Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
Gallagher S; Hughes E; Wagner S; Tshiaba P; Rosenthal E; Roa BB; Kurian AW; Domchek SM; Garber J; Lancaster J; Weitzel JN; Gutin A; Lanchbury JS; Robson M
JAMA Netw Open; 2020 Jul; 3(7):e208501. PubMed ID: 32609350
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
4. A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
Li Y; Arellano AR; Bare LA; Bender RA; Strom CM; Devlin JJ
Value Health; 2017 Apr; 20(4):547-555. PubMed ID: 28407996
[TBL] [Abstract][Full Text] [Related]
5. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
[TBL] [Abstract][Full Text] [Related]
6. Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast.
Yadav S; Hu C; Nathanson KL; Weitzel JN; Goldgar DE; Kraft P; Gnanaolivu RD; Na J; Huang H; Boddicker NJ; Larson N; Gao C; Yao S; Weinberg C; Vachon CM; Trentham-Dietz A; Taylor JA; Sandler DR; Patel A; Palmer JR; Olson JE; Neuhausen S; Martinez E; Lindstrom S; Lacey JV; Kurian AW; John EM; Haiman C; Bernstein L; Auer PW; Anton-Culver H; Ambrosone CB; Karam R; Chao E; Yussuf A; Pesaran T; Dolinsky JS; Hart SN; LaDuca H; Polley EC; Domchek SM; Couch FJ
J Clin Oncol; 2021 Dec; 39(35):3918-3926. PubMed ID: 34672684
[TBL] [Abstract][Full Text] [Related]
7. Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Desmond A; Kurian AW; Gabree M; Mills MA; Anderson MJ; Kobayashi Y; Horick N; Yang S; Shannon KM; Tung N; Ford JM; Lincoln SE; Ellisen LW
JAMA Oncol; 2015 Oct; 1(7):943-51. PubMed ID: 26270727
[TBL] [Abstract][Full Text] [Related]
8. The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing.
Murphy CD; Lee JM; Drohan B; Euhus DM; Kopans DB; Gadd MA; Rafferty EA; Specht MC; Smith BL; Hughes KS
Cancer; 2008 Dec; 113(11):3116-20. PubMed ID: 18932252
[TBL] [Abstract][Full Text] [Related]
9. Genetic risk assessment and prevention: the role of genetic testing panels in breast cancer.
Lerner-Ellis J; Khalouei S; Sopik V; Narod SA
Expert Rev Anticancer Ther; 2015; 15(11):1315-26. PubMed ID: 26523341
[TBL] [Abstract][Full Text] [Related]
10. Screening for familial cancer risk: Focus on breast cancer.
Rousset-Jablonski C; Gompel A
Maturitas; 2017 Nov; 105():69-77. PubMed ID: 28818315
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers.
Weidner AE; Liggin ME; Zuniga BI; Tezak AL; Wiesner GL; Pal T
Cancer; 2020 Apr; 126(8):1651-1655. PubMed ID: 31967672
[TBL] [Abstract][Full Text] [Related]
12. Association of Family Cancer History With Pathogenic Variants in Specific Breast Cancer Susceptibility Genes.
Kurian AW; Abrahamse P; Ward KC; Hamilton AS; Deapen D; Berek JS; Hoang L; Yussuf A; Dolinsky J; Brown K; Slavin T; Hofer TP; Katz SJ
JCO Precis Oncol; 2021; 5():. PubMed ID: 34977446
[TBL] [Abstract][Full Text] [Related]
13. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal adherence to breast cancer surveillance following cancer genetic testing in an integrated health care system.
Knerr S; Guo B; Wernli KJ; Mittendorf KF; Feigelson HS; Gilmore MJ; Jarvik GP; Kauffman TL; Keast E; Liles EG; Lynch FL; Muessig KR; Okuyama S; Veenstra DL; Zepp JM; Wilfond BS; Devine B; Goddard KAB
Breast Cancer Res Treat; 2023 Oct; 201(3):461-470. PubMed ID: 37470892
[TBL] [Abstract][Full Text] [Related]
15. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
16. High likelihood of actionable pathogenic variant detection in breast cancer genes in women with very early onset breast cancer.
Evans DG; van Veen EM; Byers HJ; Evans SJ; Burghel GJ; Woodward ER; Harkness EF; Eccles DM; Greville-Haygate SL; Ellingford JM; Bowers NL; Pereira M; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ
J Med Genet; 2022 Feb; 59(2):115-121. PubMed ID: 33758026
[TBL] [Abstract][Full Text] [Related]
17. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F
Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467
[TBL] [Abstract][Full Text] [Related]
19. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Tung N; Battelli C; Allen B; Kaldate R; Bhatnagar S; Bowles K; Timms K; Garber JE; Herold C; Ellisen L; Krejdovsky J; DeLeonardis K; Sedgwick K; Soltis K; Roa B; Wenstrup RJ; Hartman AR
Cancer; 2015 Jan; 121(1):25-33. PubMed ID: 25186627
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]